Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation allocations rather than operational financial performance.
Material Changes
On June 28, 2013, Non-Executive Directors received allocations of notional Ordinary Shares and American Depositary Shares (ADSs) for the service period of April 1, 2013, to June 30, 2013. The allocation prices were set at £16.39 per Ordinary Share and $49.95 per ADS. These allocations were formally notified to the Company and Directors on July 1, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Allocation Date: June 28, 2013.
- Service Period: April 1, 2013, to June 30, 2013.
- Share Prices: Ordinary Shares at £16.39; ADSs at $49.95.
- Recipients: Allocations were made to 12 Non-Executive Directors, including Sir Christopher Gent, Professor Sir Roy Anderson, and Dr Stephanie Burns.
- Notification Date: July 1, 2013.